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Pemphigus vulgaris and pemphigus foliaceus are two
closely related, but clinically and histologically distinct,
autoimmune skin diseases. The autoantigens for
pemphigus vulgaris and pemphigus foliaceus are
desmoglein 3 and desmoglein 1, respectively. The
anti-desmoglein 1 antibodies in pemphigus foliaceus
and anti-desmoglein 3 antibodies in pemphigus
vulgaris are pathogenic as determined by immuno-
globulin G passive transfer animal models. More
than 50% of pemphigus vulgaris sera also contain
anti-desmoglein 1 autoantibodies; however, the patho-
genicity of the anti-desmoglein 1 autoantibodies in
pemphigus vulgaris remains unknown. In this study,
we used soluble recombinant extracellular domains of
desmoglein 1 and desmoglein 3 to obtain affinity-
purified anti-desmoglein 1 and anti-desmoglein
Pemphigus vulgaris (PV) and pemphigus foliaceus (PF)are the two major subtypes of pemphigus, a group ofautoimmune blistering diseases affecting the skin andmucous membranes (Lever, 1953; Beutner and Jordon,1964). Although both PV and PF involve acantholysis
(the loss of cell-to-cell adhesion) and blister formation, they are
clinically and histologically distinguishable. PV targets the skin and
mucosal epithelia, whereas PF affects only the epidermis (Rivitti
et al, 1994). In PV, the acantholysis is observed just above the basal
cell layer (the suprabasilar layer), whereas in PF the acantholysis
occurs in the upper part of the epidermis, at the level of the
granular layer (Lever, 1965). PV and PF patients have circulating
autoantibodies directed against cell surface antigens of epidermal
keratinocytes. These autoantibodies are pathogenic as determined
by the passive transfer studies in which IgG isolated from sera of
pemphigus patients were injected into neonatal mice and induced
acantholysis with the classic immunohistologic features seen in
human patients (Anhalt et al, 1982, 1986; Roscoe et al, 1985; Jones
et al, 1988; Futamura et al, 1989). The pathogenic PF and PV
autoantibodies are predominantly IgG4 (Rock et al, 1989; Ding
et al, 1997).
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3 autoantibodies from pemphigus vulgaris sera and
examined the pathogenicity of each fraction separately
using the passive transfer mouse model. By immuno-
precipitation, the purified anti-desmoglein 1 and
anti-desmoglein 3 showed no cross-reactivity. The
anti-desmoglein 1 autoantibodies in pemphigus vul-
garis induced typical pemphigus foliaceus lesions in
neonatal mice, whereas the anti-desmoglein 3 fraction
induced pemphigus vulgaris-like lesions. In addition,
the pathogenic anti-desmoglein 1 and anti-desmoglein
3 autoantibodies in pemphigus vulgaris had predomin-
ant IgG4 subclass specificity. These findings suggest
that the anti-desmoglein 1 antibodies in pemphigus
vulgaris are pathogenic. Key words: acantholysis/
autoimmunity/cell adhesion/desmosome. J Invest Dermatol
112:739–743, 1999
PV and PF autoantibodies recognize a 130 kDa and a 160 kDa
desmosomal glycoprotein, respectively (Stanley et al, 1982, 1984;
Eyre and Stanley, 1987; Calvanico et al, 1991). Both these
autoantigens belong to the desmoglein subfamily of the cadherin
superfamily, a class of molecules that play an important part in
mediating cell-to-cell adhesion (Amagai et al, 1991; Ringwald
et al, 1987; Takeichi, 1987; Goodwin et al, 1990; Wheeler et al,
1991; Stanley, 1993). The PF antigen is designated desmoglein
1 (Dsg1) and the PV antigen is designated desmoglein 3 (Dsg3).
By indirect immunofluorescence (IF), Dsg1-specific autoantibodies
stain keratinocyte cell surfaces predominantly in the upper
part of the epidermis, whereas Dsg3-specific autoantibodies
predominantly stain the basal and immediate suprabasal layers of
the epidermis (Arnemann et al, 1993; Amagai et al, 1996; Koch
et al, 1997; Shirakata et al, 1998). Anti-Dsg3 autoantibodies in
PV and anti-Dsg1 autoantibodies in PF have been shown to be
pathogenic (Amagai et al, 1992, 1994, 1995; Memar et al, 1996).
The expression of Dsg1 and Dsg3 in the epidermis corresponds
precisely to the site where blisters appear in PF and PV,
respectively. Interestingly, over 50% of PV sera recognize both
Dsg3 and Dsg1, whereas no PF sera have been found to cross-
react with Dsg3 (Eyre and Stanley, 1987; Hashimoto et al, 1990;
Dmochowski et al, 1992; Amagai et al, 1995; Emery et al, 1995;
Ding et al, 1997). In this study we determined whether the
anti-Dsg1 autoantibodies in PV are pathogenic. Anti-Dsg1 and
anti-Dsg3 autoantibodies in PV sera were affinity-purified using
the full length of extracellular domains of Dsg1 and Dsg3
expressed in the baculovirus system. Each IgG fraction was then
characterized by immunoblotting and immunoprecipitation and
assayed for pathogenicity by passive transfer experiments.
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Figure 1. Schematic diagram of the recombinant extracellular
domain of Dsg1.His (rDsg1.His) and Dsg3.His (rDsg3.His).
rDsg1.His and rDsg3.His were constructed and expressed in a baculovirus
expression system. Both proteins contain a signal sequence (S), a propeptide
(P), and the entire extracellular domain (EC1–5) linked to a six-histidine
tail. The black strips represent the Ca21-binding sites.
MATERIALS AND METHODS
Source of sera Two PV sera (PV1 and PV2) containing both anti-Dsg1
and anti-Dsg3 antibodies were used in this study. One PV serum (Lef)
containing only Dsg3 antibodies with generalized disease and one PF serum
(Celio) were used as positive controls. Both PV1 and PV2 had the
characteristic clinical and histologic diagnosis of PV. Both had generalized
disease involving both the skin and the mucous membranes. By indirect
IF both patients had titers .1:160 against human skin and mouse skin. In
PV1 the relative titers of the anti-Dsg1 and anti-Dsg3 were 1 : 80 and
1:320, respectively. In PV2 the relative titers of the anti-Dsg1 and anti-
Dsg3 were 1:160 and 1:320, respectively. Celio had clinical and histologic
diagnosis of PF and exhibited an indirect IF titer of 1:320 against human
and mouse skin. A rabbit anti-human Dsg1 anti-serum (corresponding to
amino acids 76–158) and rabbit anti-human Dsg3 (corresponding to amino
acids 145–192) were also used.
The expression of the extracellular domains of Dsg1 and Dsg3
using the baculovirus expression system The expression of the entire
extracellular domain of Dsg3 using the baculovirus system was described
previously (Ding et al, 1997). The recombinant protein is soluble and fully
conformational (Ding et al, 1997). In order to affinity-purify anti-Dsg3
autoantibodies, the expression vector was re-engineered by adding a stretch
of six-histidine codons (59-GAT CTG AGC ACC ATC ATC ACC ATC
ACG CGC GCT AG-39) immediately downstream of the Dsg3 extracellular
domain (see Fig 1). Similarly, the expression vector for the entire
extracellular domain of Dsg1 with a histidine tag was also constructed.
The junction regions and inserts in the vector PVL1393 were sequenced
to insure sequence integrity. The recombinant proteins were expressed
following the same procedure as previously described (Ding et al, 1997).
Affinity-purification of anti-Dsg1 and anti-Dsg3 autoantibodies
from PV sera The affinity columns were generated according to the
previously described procedure (Gu et al, 1994). In brief, 100 ml of cell
culture supernatant containing about 10 mg of the recombinant Dsg1 or
Dsg3 protein was incubated with 4 ml Ni-NTA agarose (QIAGEN,
Chatsworth, CA) at room temperature for 1 h with gentle shaking. The
mixture was packed into a column, washed and equilibrated in Tris-
buffered saline/Ca21 buffer (10 mM Tris, 145 mM NaCl, 5 mM CaCl2,
pH 7.5). Three milliliters total IgG isolated from PV sera by 50% ammonium
sulfate precipitation was loaded on to the column. The column was washed
with 10 bed volumes of Tris-buffered saline/Ca21, followed by 10 bed
volumes of low salt washing buffer (150 mM NaCl, 50 mM Tris, pH 7.5)
and the same volume of high salt washing buffer (1 M NaCl, 50 mM Tris,
pH 7.5). The bound anti-Dsg1 or anti-Dsg3 antibodies were then eluted
with 4 M MgCl2 buffer. The affinity-purified IgG was concentrated by a
Centricon-30 concentrator (Amicon, Beverly, MA).
Immunologic characterization of the anti-Dsg1 and anti-Dsg3
antibodies The affinity-purified anti-Dsg1 and anti-Dsg3 antibodies
were analyzed by immunoblotting, indirect IF and immunoprecipitation.
For immunoblotting (Ding et al, 1997), the baculovirus expressed rDsg1
and rDsg3 extracellular domains were resolved by 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and subsequently
transferred to a nitrocellulose membrane. The membrane was incubated
with a rabbit anti-human Dsg1 anti-serum, rabbit anti-human Dsg3 anti-
serum, purified anti-Dsg1 autoantibodies, purified anti-Dsg3 autoantibodies
or controls. For indirect IF, the purified autoantibodies were applied to
human skin cryosections and then stained by fluorescein isothiocyanate-
conjugated goat anti-human IgG as previously described (Matis et al, 1987).
The IgG subclass was determined using human IgG subclass-specific
monoclonal antibodies (ATCC, Rockville, MD) (Rock et al, 1989). The
immunoprecipitation experiments were performed as previously reported
Figure 2. Immunoblotting analysis of recombinant extracellular
domains of Dsg1 and Dsg3. rDsg1 and rDsg3 were electrophoresed by
10% SDS–PAGE, transferred to a nitrocellular filter and blotted with a
polyclonal rabbit anti-Dsg1 (lanes 1 and 2) or rabbit anti-Dsg3 antibody
(lanes 3 and 4). Lanes 1 and 3, Hi-5 cell culture medium; lane 2, medium
from Hi-5 cells infected with rDsg1.His baculovirus; lane 4, medium from
Hi-5 cells infected with rDsg3.His baculovirus.
(Calvanico et al, 1991; Olague-Alcala et al, 1994; Ding et al, 1997). Briefly,
recombinant Dsg1 or Dsg3 was iodinated using chloramine-T and incubated
with anti-Dsg1 or anti-Dsg3 antibodies. The soluble immune complexes
were mixed with Staphylococcus aureus cells containing staphylococcal protein
A (Sigma, St. Louis, MO). The bound IgG and antigen were then eluted
with 1 3 SDS sample buffer and analyzed by 10% SDS–PAGE gels under
denatured and reducing conditions. The gels were dried and the bands
were visualized by autoradiography.
Laboratory animals Breeding pairs of BALB/C mice were purchased
from Jackson Laboratories (Bar Harbor, ME) and maintained at the Medical
College of Wisconsin Animal Resource Center. Neonatal mice (24–36 h
old with body weights between 1.4 and 1.6 g) were used for passive
transfer experiments.
Induction of experimental pemphigus and animal evaluation A
100 µl aliquot of affinity-purified anti-Dsg1 or anti-Dsg3 antibodies
(0.56–0.8 mg per g body weight) in PBS was administered to neonatal
mice by intradermal (i.d.) injection. The injection techniques have been
described elsewhere (Liu et al, 1997). The skin of neonatal mice from the
test and control groups was examined 20 h after the IgG injection. The
animals were then killed and the following specimens were obtained. Skin
sections were taken for light microscopy (hematoxylin and eosin staining)
and for direct IF analysis to detect in vivo bound human IgG. Sera of
injected animals were obtained for indirect IF to determine the circulating
titers of anti-Dsg1 and anti-Dsg3 IgG. Direct and indirect IF analyses were
performed as previously described (Hashimoto et al, 1990). Monospecific
fluorescein isothiocyanate-conjugated-conjugated goat anti-human IgG
was obtained commercially (Kirkeggard & Perry Laboratories, Gaithers-
burg, MD).
RESULTS
The production of recombinant Dsg1 and Dsg3 We have
previously reported the expression of the extracellular domain of
Dsg3 in the baculovirus system and demonstrated that the recombin-
ant Dsg3 extracellular domain is soluble and exhibits conformational
epitopes by immunoprecipitation (Ding et al, 1997). In this study,
we re-engineered the expression construct and added a six histidine-
tag (His-tag) to the C-terminus of the protein to facilitate affinity
purification of the recombinant Dsg3 (rDsg3-His) and Dsg3-specific
autoantibodies (Fig 1). Similarly, we also expressed the entire
extracellular domain of Dsg1 with a C-terminal His-tag (rDsg1-
His) (Fig 1). Immunoblot analysis of these baculovirus expressed
recombinant proteins using rabbit antisera directed against human
Dsg1 and Dsg3 is shown in Fig 2. The rabbit anti-Dsg1 antibodies
reacted with the 70 kDa rDsg1-His in culture medium of Hi-5
cells infected with rDsg1-His baculovirus (Fig 2, lane 2). The
rabbit anti-Dsg3 antibodies specifically recognized the 67 kDa
rDsg3-His (Fig 2, lane 4). No bands were shown in control media
(Fig 2, lanes 1 and 3). The same immunoblotting results were
obtained with PF and PV sera and purified anti-Dsg1 and anti-
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Figure 3. The immune specificity of affinity purified anti-Dsg1 and
anti-Dsg3 from PV patients. Anti-Dsg1 and anti-Dsg3 antibodies were
purified from two PV patients by using a rDsg1 or rDsg3 affinity column,
respectively. The purified anti-Dsg1 or anti-Dsg3 antibodies were used to
immunoprecipitate 125I-labeled rDsg1.His (a) and rDsg3.His (b). The
precipitates were fractionated on a 10% SDS–PAGE and visualized by
autoradiography. Lanes 1 and 6, positive control sera (P) (a, PF serum; b,
PV serum); lanes 2 and 7, normal control sera (N); lanes 3 and 8, total IgG
from PV patients; lanes 4 and 9, affinity purified anti-Dsg3 antibodies; lanes
5 and 10, affinity purified anti-Dsg1 antibodies.
Dsg3 autoantibodies (data not shown). These findings show that
the baculovirus expressed rDsg1 and rDsg3 extracellular domains
are soluble and reactive with anti-Dsg1 and anti-Dsg3 antibodies,
respectively.
Anti-Dsg1 and anti-Dsg3 autoantibodies in PV sera are not
cross-reactive To determine whether anti-Dsg1 and anti-Dsg3
antibodies have cross-reactivity, Dsg1 and Dsg3-specific antibodies
in PV sera (PV1 and PV2) were separated using rDsg1-His and
rDsg3-His affinity columns. The anti-Dsg1 antibodies from a PF
serum (Celio) and anti-Dsg3 antibodies from a PV serum (Lef),
which lacks anti-Dsg1 activity, were also purified using the same
affinity columns and used as positive controls. The purified IgG
preparations were then analyzed by immunoprecipitation. As shown
in Fig 3, the rDsg1-His was recognized by control anti-Dsg1 IgG
from the PF serum Celio (Fig 3a, lanes 1 and 6), total IgG from
PV1 and PV2 (Fig 3a, lanes 3 and 8), and anti-Dsg1 IgG from
PV1 and PV2 (Fig 3a, lanes 5 and 10). The rDsg1-His, however,
was not recognized by anti-Dsg3 IgG from PV1 and PV2 (Fig 3a,
lanes 4 and 9), nor by normal control human IgG (Fig 3a, lanes 2
and 7). Similarly, the rDsg3-His reacted with control anti-Dsg3
IgG from the PV serum Lef (Fig 3b, lanes 1 and 6), total IgG from
PV1 and PV2 (Fig 3b, lanes 3 and 8), as well as anti-Dsg3 IgG
from PV1 and PV2 (Fig 3b, lanes 4 and 9). In contrast, the
rDsg3-His was not reactive with anti-Dsg1 IgG from PV1 and
PV2 (Fig 3b, lanes 5 and 10), nor with normal control human IgG
(Fig 3b, lanes 2 and 7). These results demonstrate that the anti-
Dsg1 autoantibodies in PV sera do not cross-react with Dsg3 and
the anti-Dsg3 autoantibodies do not cross-react with Dsg1.
Anti-Dsg1 autoantibodies in PV sera induce PF-like acantho-
lysis in mice To test whether anti-Dsg1 antibodies in PV sera
are pathogenic, neonatal BALB/C mice were injected intradermally
with the affinity-purified anti-Dsg1 IgG from PV sera and from
the PF serum Celio. Mice (n 5 6) injected with anti-Dsg1 IgG
from PV sera developed clinical blisters (Fig 4A, also see Table I).
Direct IF of the skin of the injected animals showed binding
of anti-Dsg1 antibodies to the intercellular space of subcorneal
keratinocytes (Fig 4B). Hematoxylin and eosin examination of the
lesional skin revealed subcorneal acantholysis (Fig 4C). These
immunohistologic features are identical to those found in mice
(n 5 5) injected with anti-Dsg1 IgG from PF sera (Table I). As
expected, mice (n 5 6) injected i.d. with the affinity-purified anti-
Dsg3 IgG from the PV sera developed blisters (Fig 4D, also see
Figure 4. Pathogenicity of affinity purified anti-Dsg1 and anti-
Dsg3. Neonatal BALB/C mice were injected i.d. with anti-Dsg1 (A–C)
or anti-Dsg3 (D–F) (0.56–0.8 mg per g body weight), respectively. The
clinical, immunologic, and histologic examinations were performed 20 h
post IgG injection. Nikolskey sign was seen in mice injected with both
anti-Dsg1 (A) and anti-Dsg3 antibodies (D). Direct IF showed the binding
of anti-Dsg1 antibodies to the intercellular spaces of subcorneal keratinocytes
(B), whereas the binding of anti-Dsg3 were shown to locate to the
suprabasal layer of the murine epidermis (E). Hematoxylin and eosin
examination demonstrated that anti-Dsg1 antibodies induce subcorneal
acantholysis (C), whereas anti-Dsg3 antibodies produce suprabasilar
acantholysis (F) in neonatal mice. Site of basal keratinocytes (arrow in B–
F). Original magnification, 3200.
Table I). Direct IF of the skin of the mice showed the deposition
of anti-Dsg3 antibodies at the suprabasal layer of the epidermis
(Fig 4E) and hematoxylin and eosin staining of the lesion skin
revealed suprabasal acantholysis (Fig 4F). Affinity-purified anti-
Dsg3 IgG from the positive control PV serum Lef induced a similar
phenotype in neonatal mice (n 5 5, Table I). These results
demonstrate that, like anti-Dsg1 autoantibodies in PF, anti-Dsg1
IgG in PV are indeed pathogenic and induce typical PF lesions
in mice.
The pathogenic anti-Dsg1 autoantibodies in PV belong to
the IgG4 subclass The subclass of anti-Dsg1 IgG in PV was
determined by indirect IF using human and mouse skin as substrates.
The predominant IgG subclass of the anti-Dsg1 antibodies in PV
was IgG4 with minimal other IgG subclasses (Table I). The anti-
Dsg3 antibodies in these PV sera were also IgG4 (Table I). These
results demonstrate that, like anti-Dsg1 antibodies in PF, the
pathogenic anti-Dsg1 and anti-Dsg3 IgG in PV are also pre-
dominantly of the IgG4 subclass.
DISCUSSION
It is well documented that in addition to anti-Dsg3 antibodies,
more than 50% of PV sera also contain anti-Dsg1 activity (Eyre
et al, 1987; Hashimoto et al, 1990; Dmochowski et al, 1992; Amagai
et al, 1995; Emery et al, 1995; Ding et al, 1997; Ishii et al, 1997).
In this study, we provide direct evidence that Dsg1-specific
autoantibodies in PV are pathogenic. The affinity-purified anti-
Dsg1 antibodies from PV sera that contain both anti-Dsg1 and
anti-Dsg3 IgG were able to induce cutaneous lesions in neonatal
mice. Interestingly, the clinical and immunohistologic features of
these mice are identical to the mice injected with pathogenic anti-
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Table I. Pathogenicity and IgG subclass of affinity-purified anti-Dsg1 and anti-Dsg3 antibodies from PV sera
IgG injecteda IgG subclassb Number of mice Disease activityc Lesional site (H/E) Direct IFd
PV1:αDsg1 IgG4 6 31 granular 1
PV1:αDsg3 IgG4 6 21 suprabasilar 1
PV2:αDsg1 IgG4 6 31 granular 1
PV2:αDsg3 IgG4 6 31 suprabasilar 1
Celio:αDsg1 IgG4 5 31 granular 1
Lef:αDsg3 IgG4 5 31 suprabasilar 1
aNeonatal BALB/C mice were injected intradermally with 100 µl of affinity-purified anti-desmoglein 1 (Dsg1) or anti-Dsg3 autoantibodies. PV1 and PV2 sera contained
both anti-Dsg1 and anti-Dsg3 activities. Celio was PF serum containing only anti-Dsg1 antibodies, whereas Lef was PV serum containing only anti-Dsg3 antibodies.
bThe IgG subclass was determined by indirect IF using human and mouse skin as substrates and human IgG subclass-specific monoclonal antibodies.
cInjected animals were examined clinically 20 h after IgG injection. Disease activity is scored on a scale of ‘‘–‘‘ to ‘‘31’’: –, no detectable lesion clinically and histologically;
11, means means no evidence of clinical blister but acantholysis involving less than 25% of the epidermis at the injection site; 21, means clinical blister with acantholysis
involving 25%–50% of the epidermis at the injection site; 31, means intense blister with acantholysis involving .50% of the epidermis at the injection site. See Materials and
Methods for details.
dFor direct IF, skin sections were stained with monospecific fluorescein isothiocyanate-conjugated-conjugated goat anti-human IgG.
Dsg1 autoantibodies from PF sera. In addition, like the anti-Dsg1
antibodies in PF, the Dsg1-specific IgG in these PV sera belong to
the IgG4 subclass.
Dsg1 and Dsg3 are 46% identical at the amino acid sequence
level. It has been speculated that the presence of anti-Dsg1 reactivity
in PV sera is due to cross-reactivity of certain anti-Dsg3 antibodies
with Dsg1. The alternative is that these PV sera contain two distinct
and non-cross-reacting populations of antibodies-one against Dsg1
and the other against Dsg3. In order to discriminate between these
two possibilities, we affinity purified PV autoantibodies using
recombinant forms of Dsg1 and Dsg3 expressed in the baculovirus
system. Using these highly purified reagents, we found no cross-
reactivity between autoantibodies directed against Dsg1 and Dsg3
extracellular domains as determined by immunoblotting and
immunoprecipitation. These findings were supported by our in vivo
direct IF experiments. Dsg1-specific antibodies in PV bind mainly
to the subcorneal keratinocytes, whereas Dsg3-specific IgG in PV
predominantly deposit on the suprabasal keratinocytes. These results
are consistent with the previous findings reported (Ishii et al, 1997).
In this study, it was shown that the immune reactivity of PV sera
against Dsg3 by ELISA was abolished by preadsorption with
recombinant Dsg3 but not Dsg1. And conversely, reactivity of PV
sera with Dsg1 was blocked by preadsorption with recombinant
Dsg1 but not Dsg3.
Knowing that the anti-Dsg1 and anti-Dsg3 antibodies in PV are
not cross-reactive, we next directly assessed the pathogenicity of
the anti-Dsg1 and anti-Dsg3 antibodies in PV. The anti-Dsg3
antibodies from the PV sera caused suprabasilar acantholysis, the
characteristic feature of PV. Previously, it was shown that Dsg3
ectodomain expressed in the baculovirus system was able to block
blisters in mice induced by autoantibodies from PV sera (Amagai
et al, 1994). The authors of the report, however, did not test
directly for the pathogenic activity of the anti-Dsg1 component of
the sera, whereas we have shown that the anti-Dsg1 antibodies in
these PV sera are indeed pathogenic. Interestingly, the anti-Dsg1
antibodies in PV induced PF-like lesions in neonatal mice, even
though the patients from whom the sera were drawn had typical
PV blisters. The discrepancy between our mouse model results and
clinical observations is most likely due to the difference in anti-
Dsg1 antibody titers in those PV patients and in the injected mice
which received a high dose of the purified IgG.
It has been reported that certain patients progress from PV to
PF (Hashimoto et al, 1991, 1995; Iwatsuki et al, 1991; Kawana
et al, 1994), and this conversion is associated with a change of
autoantibody profiles from predominant anti-Dsg3 to anti-Dsg1.
One interpretation of this phenomenon is that the original auto-
immune response is directed against a pathogenic epitope on Dsg3
and later the response spreads to other epitope(s) that cross-react
with Dsg1. Our data, however, suggest an ‘‘intermolecular epitope
spreading’’ rather than an ‘‘intramolecular epitope spreading’’ mech-
anism, as anti-Dsg1 and anti-Dsg3 antibodies in PV sera are not
cross-reactive. Further investigation will be needed to address this
important issue.
In summary, our study demonstrated that the anti-Dsg1 autoanti-
bodies in PV are pathogenic and have IgG4 subclass specificity.
These findings might be helpful for further dissecting the immuno-
pathogenesis of pemphigus and developing more effective thera-
peutic strategies to manage these human autoimmune diseases.
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